Breaking News Instant updates and real-time market news.

JNJ

Johnson & Johnson

$118.21

0.65 (0.55%)

, PFE

Pfizer

$32.59

-0.0699 (-0.21%)

13:53
10/17/16
10/17
13:53
10/17/16
13:53

On The Fly: What to watch in Johnson & Johnson earnings report

Johnson & Johnson (JNJ) is scheduled to report results of its third fiscal quarter before the market open on October 18, with a conference call scheduled for 8:30 am EDT. What to watch for: 1. UPBEAT GUIDANCE: Along with its last report, J&J raised its fiscal year 2016 earnings per share view to $6.63-$6.73 from $$6.53-$6.68, versus a consensus at the time of $6.61. Analysts currently see the company reporting EPS of $6.69 this fiscal year. On July 20, the day after J&J's second quarter earnings release, research firm RBC Capital raised its price target on the drug giant to $133 from $125, keeping an Outperform rating on shares and saying, "Johnson & Johnson's pharma and consumer units delivered strong results." 2. CURRENCY: Global currency devaluations continue to be a problem for big pharma companies like J&J. Last quarter J&J reported sales of $18.5B, an increase of 3.9% as compared to the second quarter of 2015. Operational sales results increased 5.3% and the negative impact of currency was 1.4%. Domestic sales increased 7.4%. International sales increased 0.4%, reflecting operational growth of 3.1% and a negative currency impact of 2.7%. Excluding the net impact of acquisitions, divestitures and hepatitis C sales, on an operational basis, worldwide sales increased 7.9%, domestic sales increased 8.8% and international sales increased 6.9%. Operations in Venezuela negatively impacted worldwide operational sales growth by 30 basis points, and international sales growth by 70 basis points. REMICADE WORRIES: According to a Bloomberg article from August 17, a federal judge had negated an integral patent on Johnson & Johnson's "blockbuster arthritis drug Remicade." This development., according to Bloomberg, makes the possibility that Pfizer (PFE) will sell a rival copy in the U.S. According to Bloomberg, Cowen analyst Joshua Jennings said at the time, "Today's ruling is clearly a negative with the implication being that Pfizer will potentially move forward' with a risky launch in Q4. DRUG PRICING ENVIRONMENT: According to RBC Capital analyst Glenn Novarro in a note to investors on October 7, concerns about the current pharma pricing rhetoric and a Remicade biosimilar risk are "manageable/overblown." Novarro expects the company to report strong Q3 results, driven by a strong pharma performance. Novoro said he expects the company's Q3 revenue to come in slightly above expectations, and he sees the company narrowing its 2016 EPS guidance to the high end of the previous range. The analyst recommended buying the stock. He kept a $133 price target and Outperform rating on the shares.

JNJ

Johnson & Johnson

$118.21

0.65 (0.55%)

PFE

Pfizer

$32.59

-0.0699 (-0.21%)

  • 18

    Oct

  • 22

    Oct

  • 26

    Oct

  • 01

    Nov

  • 06

    Nov

JNJ Johnson & Johnson
$118.21

0.65 (0.55%)

08/24/16
JEFF
08/24/16
NO CHANGE
Target $210
JEFF
Buy
Cooper Companies estimates raised at Jefferies after doctor survey
Jefferies analyst Anthony Petrone reports that the firm's survey of 52 new optometry practices suggest continued gains in dailies and stable share in monthlies for Cooper Companies (COO) and that Johnson & Johnson's (JNJ) Acuvue Vita is off to slow start. Based on the survey results, and a "significant" foreign exchange tailwind, Petrone raised his estimates for Cooper and increased his price target on the shares to $210 from $190. The firm has a Buy rating on Cooper shares.
09/19/16
JEFF
09/19/16
NO CHANGE
Target $48
JEFF
Buy
Abbott unit sale does not impact Alere transaction, says Jefferies
Jefferies analyst Jeffrey Holford believes Abbott's (ABT) sale of its Medical Optics business to Johnson & Johnson (JNJ) does not imply an increased probability that the Alere (ALR) deal will close. After speaking to Abbott management, Holford thinks the proceeds from the sale are more likely to be targeted towards the St. Jude Medical (STJ) acquisition. He believes that deal has a higher probability of closing than Alere. Holford has a Buy rating on Abbott with a $48 price target.
09/19/16
LEER
09/19/16
NO CHANGE
LEER
Abbott, Johnson & Johnson transaction positive for both companies, says Leerink
Leerink analyst Danielle Antalffy says the sale of Abbott's (ABT) Medical Optics ophthalmology business to Johnson & Johnson (JNJ) is positive for both companies. The deal strengthens Abbott's balance sheet and eliminates the need for a previously expected $3B capital raise, and adds a key component to Johnson & Johnson's already-strong vision care franchise, the analyst notes.
10/07/16
RBCM
10/07/16
NO CHANGE
RBCM
Johnson & Johnson weakness creates buying opportunity, says RBC Capital
RBC Capital analyst Glenn Novarro says that Johnson & Johnson underperformed the market in Q3 due to a number of factors including Remicade biosimilar risk and the pharma pricing debate. The analyst says that "these concerns are manageable/overblown," and he expects the company to report strong Q3 results, driven by a strong pharma performance. Novoroo expects the company's Q3 revenue to come in slightly above expectations, and he predicts that the company will narrow its 2016 EPS guidance to the high end of the previous range. The analyst recommends buying the stock. He keeps a $133 price target and Outperform rating on the shares.
PFE Pfizer
$32.59

-0.0699 (-0.21%)

09/14/16
BMOC
09/14/16
NO CHANGE
BMOC
Pfizer should exceed fiscal 2016 guidance, says BMO Capital
BMO Capital analyst Alex Arfaei says that Pfizer should exceed its fiscal 2016 guidance. The analyst says that Medivation, which Pfizer agreed to acquire, gives Pfizer another growth driver. Additionally, Pfizer has a number of other "high margin specialty drugs," according to the analyst. He says that the stock's dividend yield is "attractive," and he keeps a $40 price target and Outperform rating on the shares.
10/07/16
ROTH
10/07/16
NO CHANGE
Target $160
ROTH
Buy
ICU Medical price target raised to $160 from $132 at Roth Capital
Roth Capital analyst Chris Lewis raised his price target for ICU Medical (ICUI) to $160 from $132 after the company announced an agreement to acquire Hospira Infusion Systems from Pfizer (PFE) for $1B. The analyst is overall positive on the deal as it removes the long-standing customer concentration overhang and grows ICU Medical into a legitimate pure-play infusion therapy company with a complete product portfolio. The company also preannounced Q3 preliminary results above expectations, he notes. Lewis reiterates a Buy rating on ICU Medical's shares.
10/13/16
JEFF
10/13/16
DOWNGRADE
Target $36
JEFF
Hold
Pfizer downgraded to Hold from Buy at Jefferies
Jefferies analyst Jeffrey Holford downgraded Pfizer (PFE) to Hold citing a lack of positive catalysts. The analyst says the drivers for his upgrade to Buy have either played out or have not materialized, namely an inversion or GEP unit separation. To reflect the infusion business disposal and weaker Ibrance trends, Holford cut his mid-term earnings estimates for Pfizer by up to 7% and cut his price target for the shares to $36 from $39. The stock closed yesterday down 6c to $33.07. The analyst also sees increased risk of a major acquisition occurring over the next 12 months. In the global pharma space, Holford lists AbbVie (ABBV), Eli Lilly (LLY), Novartis (NVS) and AstraZeneca (AZN) as his top picks.
10/13/16
10/13/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Bristol-Myers (BMY) downgraded to Buy from Conviction Buy at Goldman with analyst Jami Rubin saying disappointing CM-26 data adds a greater level of uncertainty to future trials. 2. Pfizer (PFE) downgraded to Hold from Buy at Jefferies with analyst Jeffrey Holford citing a lack of positive catalysts. 3. Coach (COH) downgraded to Mixed from Positive at OTR Global citing checks that indicate less competitive offerings, reduced promotions, and feedback of some share loss by store managers. 4. E-Trade (ETFC) downgraded to Neutral from Buy at BofA/Merrill. 5. Deckers Brands (DECK) downgraded to Negative from Neutral at Susquehanna with analyst Sam Poser saying he believes the health of the UGG brand is clearly at risk as the company has already started promotional activity. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

AOS

A.O. Smith

$54.42

1.45 (2.74%)

20:16
04/27/17
04/27
20:16
04/27/17
20:16
Downgrade
A.O. Smith rating change  »

A.O. Smith downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 09

    May

FB

Facebook

$147.70

1.14 (0.78%)

20:11
04/27/17
04/27
20:11
04/27/17
20:11
Hot Stocks
Facebook improves 'Rights Manager' content protection system »

Facebook introduced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 08

    May

  • 16

    May

AAWW

Atlas Air

$59.80

0.4 (0.67%)

20:11
04/27/17
04/27
20:11
04/27/17
20:11
Downgrade
Atlas Air rating change  »

Atlas Air downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 24

    May

UTHR

United Therapeutics

$120.50

0.51 (0.43%)

20:00
04/27/17
04/27
20:00
04/27/17
20:00
Hot Stocks
United Therapeutics announces $250M repurchase program »

United Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

CLDR

Cloudera

19:57
04/27/17
04/27
19:57
04/27/17
19:57
Syndicate
Cloudera 15M share IPO priced at $15.00, above the range »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 28

    Apr

CYTR

CytRx

$0.68

-0.121 (-15.02%)

19:56
04/27/17
04/27
19:56
04/27/17
19:56
Hot Stocks
CytRx: Former 'SPA' for aldoxorubicin no longer applicable »

CytRx disclosed in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jun

EEX

Emerald Expositions Events

19:52
04/27/17
04/27
19:52
04/27/17
19:52
Syndicate
Emerald Expositions Events 15.5M share IPO priced at $17.00 »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

GOOG

Alphabet

$874.25

2.52 (0.29%)

, GOOGL

Alphabet Class A

$891.44

2.3 (0.26%)

19:31
04/27/17
04/27
19:31
04/27/17
19:31
Hot Stocks
Google introduces development kit for Google Assistant »

Google announced in a…

GOOG

Alphabet

$874.25

2.52 (0.29%)

GOOGL

Alphabet Class A

$891.44

2.3 (0.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 02

    May

  • 16

    May

  • 22

    May

SRPT

Sarepta

$34.72

-0.14 (-0.40%)

19:26
04/27/17
04/27
19:26
04/27/17
19:26
Hot Stocks
Sarepta: 'Productive' payer talks, ramping of patient starts continuing in Q2 »

"The number of exon…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

SRPT

Sarepta

$34.72

-0.14 (-0.40%)

19:22
04/27/17
04/27
19:22
04/27/17
19:22
Hot Stocks
Sarepta: Guidance includes only U.S. sales »

"Our guidance only…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

SRPT

Sarepta

$34.72

-0.14 (-0.40%)

19:20
04/27/17
04/27
19:20
04/27/17
19:20
Hot Stocks
Sarepta: Exondys post-market commitment data likely unavailable for couple years »

"The final protocols…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

SRPT

Sarepta

$34.72

-0.14 (-0.40%)

19:18
04/27/17
04/27
19:18
04/27/17
19:18
Hot Stocks
Sarepta confirms CEO Ed Kaye to resign from role at end of current term »

Sarepta confirmed in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

BSAC

Santander Chile

$23.59

-0.36 (-1.50%)

19:02
04/27/17
04/27
19:02
04/27/17
19:02
Earnings
Santander Chile reports Q1 EPS 46c, consensus 42c »

Reports Q1 ROAE up 140…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

BA

Boeing

$183.22

1.51 (0.83%)

, BDRBF

Bombardier

$1.63

-0.0278 (-1.67%)

19:01
04/27/17
04/27
19:01
04/27/17
19:01
Hot Stocks
Canada gov't objects to Boeing allegations over Bombardier pricing in U.S. »

The Government of Canada…

BA

Boeing

$183.22

1.51 (0.83%)

BDRBF

Bombardier

$1.63

-0.0278 (-1.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

BA

Boeing

$183.22

1.51 (0.83%)

, BDRBF

Bombardier

$1.63

-0.0278 (-1.67%)

18:56
04/27/17
04/27
18:56
04/27/17
18:56
Periodicals
Boeing requests U.S. take action on Bombardier C series prices in U.S., FT says »

Boeing (BA) is aiming to…

BA

Boeing

$183.22

1.51 (0.83%)

BDRBF

Bombardier

$1.63

-0.0278 (-1.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

SWN

Southwestern Energy

$7.67

-0.16 (-2.04%)

18:48
04/27/17
04/27
18:48
04/27/17
18:48
Earnings
Southwestern Energy reports Q1 adjusted EPS 18c, consensus 18c »

Reports Q1 revenue $846M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

CRMD

CorMedix

$1.04

-0.07 (-6.31%)

18:43
04/27/17
04/27
18:43
04/27/17
18:43
Syndicate
CorMedix files to sell common stock warrants, no amount given »

H.C. Wainwright & Co.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 28

    Apr

FET

Forum Energy

$18.10

-1.05 (-5.48%)

18:39
04/27/17
04/27
18:39
04/27/17
18:39
Earnings
Breaking Earnings news story on Forum Energy »

Forum Energy sees Q2 EPS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

WDC

Western Digital

$85.71

1.1 (1.30%)

18:38
04/27/17
04/27
18:38
04/27/17
18:38
Hot Stocks
Western Digital: NAND supply-demand likely favorable through 'at least' 1H18 »

"Industry-wide…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

FET

Forum Energy

$18.10

-1.05 (-5.48%)

18:38
04/27/17
04/27
18:38
04/27/17
18:38
Earnings
Forum Energy reports Q1 adjusted EPS (14c), consensus (16c) »

Reports Q1 revenue $171M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

SJR

Shaw Communications

$21.30

0.07 (0.33%)

18:36
04/27/17
04/27
18:36
04/27/17
18:36
Hot Stocks
Shaw Communications restores internet and phone services after brief outage »

The company said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTRX

Matrix Service

$16.88

-0.575 (-3.30%)

18:33
04/27/17
04/27
18:33
04/27/17
18:33
Earnings
Breaking Earnings news story on Matrix Service »

Matrix Service sees FY17…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIMO

Gigamon

$36.00

-0.6 (-1.64%)

18:33
04/27/17
04/27
18:33
04/27/17
18:33
Earnings
Gigamon sees Q2 adjusted EPS 2c-7c, consensus 19c »

Sees Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 12

    Jun

MTRX

Matrix Service

$16.88

-0.575 (-3.30%)

18:32
04/27/17
04/27
18:32
04/27/17
18:32
Earnings
Matrix Service sees Q3 EPS (56c)-(49c), consensus 13c »

Sees Q3 revenue $250M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WDC

Western Digital

$85.71

1.1 (1.30%)

, TOSBF

Toshiba, also use TOSYY

$1.97

-0.01 (-0.51%)

18:31
04/27/17
04/27
18:31
04/27/17
18:31
Hot Stocks
Western Digital on Toshiba chip sale: Evaluating 'full range' of alternatives »

Western Digital (WDC)…

WDC

Western Digital

$85.71

1.1 (1.30%)

TOSBF

Toshiba, also use TOSYY

$1.97

-0.01 (-0.51%)

TOSYY

Toshiba, also use TOSBF

$11.89

0.07 (0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.